International Journal for Quality in Health Care 14:183-198 (2002)
© 2002 International Society for Quality in Health Care
Preventing drug-related morbidity—determining valid indicators
1School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK and
2Department of Pharmacy Health Care Administration, University of Florida, Gainesville, FL, USA
Address reprint requests to Caroline J. Morris, The Drug Usage and Pharmacy Practice Group, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester M13 9PL, UK. E-mail: caroline.j.morris{at}man.ac.uk
Objective. To describe the process that is being undertaken to validate a series of indicators for preventable drug-related morbidity—originally developed in the US—for application in the UK health care system.
Design. A two-round Delphi questionnaire survey after a preliminary validation of the indicators within the University of Manchester School of Pharmacy.
Setting. A primary care study set in the UK.
Study participants. A purposively selected sample of general practitioners with a specific responsibility for prescribing-related issues (n= 6) and pharmacists actively involved in medication review in primary care (n= 10).
Main outcome measures. The establishment of consensus among the participants that an indicator reflected preventable drug-related morbidity in primary care.
Results. After preliminary validation, 37 of the original 57 US indicators were retained. The Delphi panel generated 16 additional new indicators in the first round. At the end of the second round, the pre-defined level of consensus was reached for 29 indicators (19 of the US generated indicators; ten generated by the panel in the first round).
Conclusions. The Delphi results highlighted differences in both the clinical perspective and, possibly, philosophical viewpoints of health professionals practising in the UK and US health care systems. Further work, located in both primary and secondary care, is now in progress to operationalize. This process will form a key part of the refining, and hence further validation, of the indicators. The future development of prospective medical-record-based indicators should facilitate a reduction in the human, clinical, and economic burden of drug-related morbidity.
Keywords: adverse drug events, Delphi technique, preventable drug-related morbidity, primary care, United Kingdom, United States
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C J Morris, S Rodgers, V S Hammersley, A J Avery, and J A Cantrill Indicators for preventable drug related morbidity: application in primary care Qual. Saf. Health Care, June 1, 2004; 13(3): 181 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S Flanagan, N. J MacKinnon, S. K Bowles, and S. A Kirkland Validation of Four Clinical Indicators of Preventable Drug-Related Morbidity Ann. Pharmacother., January 1, 2004; 38(1): 20 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Earle, E. R. Park, B. Lai, J. C. Weeks, J. Z. Ayanian, and S. Block Identifying Potential Indicators of the Quality of End-of-Life Cancer Care From Administrative Data J. Clin. Oncol., March 15, 2003; 21(6): 1133 - 1138. [Abstract] [Full Text] [PDF]
|
|